Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage III Major Salivary Gland Cancer AJCC v7, Stage III Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7, Stage IVC Major Salivary Gland Cancer AJCC v7, Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7, Tongue Carcinoma
Conditions
Brief summary
This phase II trial studies how well vorinostat works in treating patients with adenoid cystic carcinoma that has come back (recurrent) or that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the efficacy by means of response rate (based on Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1 criteria) of vorinostat in the treatment of patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC). SECONDARY OBJECTIVES: I. To characterize the safety and tolerability of vorinostat in this patient population. II. To assess the time to tumor response (TTR). III. To assess the response duration (RD). IV. To evaluate progression free survival (PFS). V. To assess overall survival (OS). TERTIARY OBJECTIVES: I. To assess the association between a metabolic response by positron emission tomography (PET)/computed tomography (CT) after one cycle of chemotherapy and subsequent best tumor response according to standard anatomic response evaluation criteria (RECIST). II. To assess the association between a metabolic response by PET/CT after the first and second chemotherapy cycle and PFS. III. To assess flow sort diploid, aneuploid, and tetraploid populations of tumor cells from formalin fixed, paraffin-embedded (FFPE) tissue blocks from patients who benefited from suberoylanilide hydroxamic acid (SAHA) therapy and from patients who did not demonstrate a durable benefit. IV. Profile the genomes of each cell population using oligonucleotide comparative genomic hybridization (CGH) arrays. V. Perform whole exome analysis of the sorted tumor population and matching germ line sample for each of the patients selected. VI. To assess stable disease duration (SDD). VII. To assess the association between response to vorinostat treatment and RAD23 homolog B (HR23B) on tumor paraffin blocks. VIII. Retrospectively compare volumetric density (viable tumor volume = VTV) with pre-determined RECIST of target lesions in cross sectioning imaging (CT/magnetic resonance \[MR\]) already obtained. IX. Correlate VTV, RECIST and treatment response (partial response, stable disease, progressive disease and stable disease over 6 months). OUTLINE: Patients receive vorinostat orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed up for 180 days.
Interventions
OTHERLaboratory Biomarker Analysis
Correlative studies
DRUGVorinostat
Given PO
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed locally advanced, recurrent or metastatic adenoid cystic carcinoma * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm by chest x-ray, as \>= 10 mm with CT scan, or \>= 10 mm with calipers by clinical exam; all tumor measurements must be recorded in millimeters (or decimal fractions of centimeters) * Patients must have locally advanced and/or recurrent and/or metastatic disease not amenable to potentially curative surgery or radiotherapy; any prior number of chemotherapy regimens is allowed; a minimum of at least 4 weeks since prior chemotherapy or radiation therapy should have elapsed, 6 weeks if the last regimen included carmustine (BCNU) or mitomycin C * Life expectancy of greater than 12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky \>= 60%) * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin within normal institutional limits (WNL) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal (ULN) * Creatinine within normal institutional limits or * Creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * Eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of vorinostat will be determined following review of their case by the principal investigator * No other diagnosis of malignancy unless non-melanoma skin cancer, carcinoma in situ of the cervix, or a malignancy diagnosed \>= 5 years previously and currently with no evidence of disease; however - if the patient has had a previously diagnosed stage I/II malignancy of another type, consideration for recruitment may be made by the Cancer Therapy Evaluation Program (CTEP) senior investigator after discussion with local principal investigator (PI) and patient's physician * Confirmed availability of tumor tissue (either fresh or from paraffin block) from the primary tumor or metastatic site to be available to use on correlative studies * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign a written informed consent document * If the patient's tumor can be easily accessed, a pre-treatment biopsy will be mandatory
Exclusion criteria
* Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; more than 21 days from major surgery should have elapsed before the first dose of the study drug * Patients may not be receiving any other investigational agents or have received vorinostat in the past; patients should not have taken valproic acid for at least 4 weeks prior to enrollment * Inability to take oral medications on a continuous basis * Patients with active brain metastases should be excluded from this clinical trial; patients with previous brain metastases will be eligible if condition is treated and stable for \>= 1 month * History of allergic reactions attributed to compounds of similar chemical or biologic composition to SAHA * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with vorinostat * Patient is unable or unwilling to abide by the study protocol and to cooperate fully with the investigator or designee * Patient on current therapy with enzyme-inducing anticonvulsants
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response According to RECIST 1.1 Criteria | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | Objective (Best) response according to RECIST 1.1 criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | Toxicity will be tabulated via frequency distributions, and also dichotomized to report the proportion (and percentage) of patients experiencing a specified level (e.g., grade 3-4) of toxicity. |
| Time to Recurrence (TTR) | From the start of the treatment until the RECIST measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded, assessed up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | TTR will be summarized descriptively, reporting N, median, mean, standard deviation, standard error (SE), minimum, maximum, and 90% CI for the mean calculated from the SE and asymptotic normal distribution theory. |
| Response Duration (RD) | From the time measurement criteria are met for CR or PR (whichever is first) until the first date that recurrence or progression is objectively documented, assessed up to 60 months after the last dose of vorinostat max. treatment duration= 24 months | Median point estimate and full range will be documented, since only two patients achieved a response. |
| Progression-free Survival (PFS) | From start of treatment to time of progression or death, whichever occurs first, assessed up to 60 months after the last dose of vorinostat maximum treatment duration= 24 months | Distribution will be estimated using standard survival analysis techniques, and the K-M method. From the K-M life tables, both median point estimate and 90% confidence interval (CI) estimate. |
| Overall Survival (OS) | From the start of treatment until death from any cause, duration for reported probability= 1 year; survival data collected for up to a total of 60 months | Distribution will be estimated using standard survival analysis techniques, and the K-M method. From the K-M life tables, both point and 90% CI estimates of various statistics of interest can be calculated (e.g., median, 6-month event-free rate, 12-month event-free rate, etc.). Statistical graphs of each K-M curve (with 90% CI lines) will be generated for visual display. (One year survival rate will be given since OS median was not reached due to too few events) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Stable Disease Duration (SDD) | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | SDD will be reported as descriptive results as a median point estimate and a 90% confidence interval (CI) estimate. |
| Metabolic Response by PET/CT Scan | Up to 56 days | Will assess the association between a metabolic response by PET/CT after one course of chemotherapy and subsequent best tumor response according to standard anatomic response evaluation criteria. Will also assess the association between a metabolic response by PET/CT after the first and second chemotherapy courses and PFS. |
| Expression Level of HR23B | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | Exact logistic modeling investigation would yield a point and 90% CI estimate of the odds ratio for response. |
| Number of Patients With Flow Sort Diploid Populations of Tumor Cells From FFPE Tissue Blocks | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | Number of patients with Flow sort diploid populations of tumor cells from FFPE tissue blocks reported as a count of participants. |
| Number of Patients With Flow Sort Aneuploid Populations of Tumor Cells From FFPE Tissue | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | Number of patients with Flow sort aneuploid populations of tumor cells from FFPE tissue. Reported as descriptive results. |
| Number of Patients With Flow Sort Tetraploid Populations of Tumor Cells From FFPE Tissue | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | Number of patients with Flow sort tetraploid populations of tumor cells from FFPE tissue. Reported as descriptive results. |
| Unique Probes on the Oligonucleotide CGH Array as a Measure of the Genomic Profile of Each Cell Population. | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | Genomic profile of each cell population using oligonucleotide CGH arrays. Reported as unique probes on the CGH array. |
| The Number of Genes Sequenced in the WES Assay as a Measure of the Whole Exome Profile of the Sorted Tumor Population and Matching Germ Line Sample | Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months | Reported as descriptive results. The combined CGH array and exome data will be mined to identify genes and pathways that are targeted by select somatic events in each of the patient subsets. |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Vorinostat) Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Vorinostat: Given PO | 30 |
| Total | 30 |
Baseline characteristics
| Characteristic | Treatment (Vorinostat) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 5 Participants |
| Age, Categorical Between 18 and 65 years | 25 Participants |
| Age, Continuous | 53 years |
| Race/Ethnicity, Customized African American | 3 Participants |
| Race/Ethnicity, Customized Asian | 2 Participants |
| Race/Ethnicity, Customized Caucasian | 24 Participants |
| Race/Ethnicity, Customized Middle Eastern | 1 Participants |
| Region of Enrollment Canada | 5 participants |
| Region of Enrollment United States | 25 participants |
| Sex: Female, Male Female | 19 Participants |
| Sex: Female, Male Male | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 3 / 30 |
| other Total, other adverse events | 30 / 30 |
| serious Total, serious adverse events | 20 / 30 |
Outcome results
Primary
Objective Response According to RECIST 1.1 Criteria
Objective (Best) response according to RECIST 1.1 criteria.
Time frame: Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Vorinostat) | Objective Response According to RECIST 1.1 Criteria | Partial Response | 2 Participants |
| Treatment (Vorinostat) | Objective Response According to RECIST 1.1 Criteria | Stable Disease | 27 Participants |
| Treatment (Vorinostat) | Objective Response According to RECIST 1.1 Criteria | Progressive Disease | 1 Participants |
Secondary
Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0
Toxicity will be tabulated via frequency distributions, and also dichotomized to report the proportion (and percentage) of patients experiencing a specified level (e.g., grade 3-4) of toxicity.
Time frame: Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Hypophosphatemia | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Hypoxia | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Non cardiac chest pain | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Oral pain | 2 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Appendicitis | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Atelectasis | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Bronchial obstruction | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Bronchopulmonary hemorrhage | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Cataract | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Diarrhea | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Fatigue | 3 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Headache | 2 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Hypertension | 3 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Lung infection | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Lymphocyte count decreased | 7 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Lymphocyte count increased | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Menorrhagia | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Mucositis oral | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Platelet count decreased | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | PNEUMONIA | 1 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Thromboembolic event | 2 Participants |
| Treatment (Vorinostat) | Number of Participants With Grade 3 or Grade 4 Toxicity as Assessed by the Common Terminology Criteria for Adverse Events Version 4.0 | Wound complication | 1 Participants |
Secondary
Overall Survival (OS)
Distribution will be estimated using standard survival analysis techniques, and the K-M method. From the K-M life tables, both point and 90% CI estimates of various statistics of interest can be calculated (e.g., median, 6-month event-free rate, 12-month event-free rate, etc.). Statistical graphs of each K-M curve (with 90% CI lines) will be generated for visual display. (One year survival rate will be given since OS median was not reached due to too few events)
Time frame: From the start of treatment until death from any cause, duration for reported probability= 1 year; survival data collected for up to a total of 60 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Vorinostat) | Overall Survival (OS) | 88 percentage of participants surviving 1yr |
Secondary
Progression-free Survival (PFS)
Distribution will be estimated using standard survival analysis techniques, and the K-M method. From the K-M life tables, both median point estimate and 90% confidence interval (CI) estimate.
Time frame: From start of treatment to time of progression or death, whichever occurs first, assessed up to 60 months after the last dose of vorinostat maximum treatment duration= 24 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Vorinostat) | Progression-free Survival (PFS) | 11.4 months |
Secondary
Response Duration (RD)
Median point estimate and full range will be documented, since only two patients achieved a response.
Time frame: From the time measurement criteria are met for CR or PR (whichever is first) until the first date that recurrence or progression is objectively documented, assessed up to 60 months after the last dose of vorinostat max. treatment duration= 24 months
Population: Only 2 patients achieved a response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Vorinostat) | Response Duration (RD) | 30.1 months |
Secondary
Time to Recurrence (TTR)
TTR will be summarized descriptively, reporting N, median, mean, standard deviation, standard error (SE), minimum, maximum, and 90% CI for the mean calculated from the SE and asymptotic normal distribution theory.
Time frame: From the start of the treatment until the RECIST measurement criteria are met for complete response (CR) or partial response (PR) (whichever is first recorded, assessed up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Population: Only 2 patients achieved a response.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Treatment (Vorinostat) | Time to Recurrence (TTR) | 8.85 months |
Other Pre-specified
Expression Level of HR23B
Exact logistic modeling investigation would yield a point and 90% CI estimate of the odds ratio for response.
Time frame: Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Population: HR23B was not measured in any participant.
Other Pre-specified
Metabolic Response by PET/CT Scan
Will assess the association between a metabolic response by PET/CT after one course of chemotherapy and subsequent best tumor response according to standard anatomic response evaluation criteria. Will also assess the association between a metabolic response by PET/CT after the first and second chemotherapy courses and PFS.
Time frame: Up to 56 days
Population: We did not have funding to incorporate other imaging modalities, (such as PET/CT), or to utilize other measurement criteria (such as volumetric assessment). Therefore, these data were not collected
Other Pre-specified
Number of Patients With Flow Sort Aneuploid Populations of Tumor Cells From FFPE Tissue
Number of patients with Flow sort aneuploid populations of tumor cells from FFPE tissue. Reported as descriptive results.
Time frame: Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Population: The two cases that had FFPE blocks for the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Vorinostat) | Number of Patients With Flow Sort Aneuploid Populations of Tumor Cells From FFPE Tissue | 0 Participants |
Other Pre-specified
Number of Patients With Flow Sort Diploid Populations of Tumor Cells From FFPE Tissue Blocks
Number of patients with Flow sort diploid populations of tumor cells from FFPE tissue blocks reported as a count of participants.
Time frame: Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Population: the two cases that had FFPE blocks for the study
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Vorinostat) | Number of Patients With Flow Sort Diploid Populations of Tumor Cells From FFPE Tissue Blocks | 2 Participants |
Other Pre-specified
Number of Patients With Flow Sort Tetraploid Populations of Tumor Cells From FFPE Tissue
Number of patients with Flow sort tetraploid populations of tumor cells from FFPE tissue. Reported as descriptive results.
Time frame: Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Population: The two cases that had FFPE blocks for the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Vorinostat) | Number of Patients With Flow Sort Tetraploid Populations of Tumor Cells From FFPE Tissue | 2 Participants |
Other Pre-specified
Stable Disease Duration (SDD)
SDD will be reported as descriptive results as a median point estimate and a 90% confidence interval (CI) estimate.
Time frame: Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Vorinostat) | Stable Disease Duration (SDD) | 11.4 months |
Other Pre-specified
The Number of Genes Sequenced in the WES Assay as a Measure of the Whole Exome Profile of the Sorted Tumor Population and Matching Germ Line Sample
Reported as descriptive results. The combined CGH array and exome data will be mined to identify genes and pathways that are targeted by select somatic events in each of the patient subsets.
Time frame: Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Population: One of the cases that had FFPE blocks for the study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Vorinostat) | The Number of Genes Sequenced in the WES Assay as a Measure of the Whole Exome Profile of the Sorted Tumor Population and Matching Germ Line Sample | 21,522 Genes sequenced in the WES assay. |
Other Pre-specified
Unique Probes on the Oligonucleotide CGH Array as a Measure of the Genomic Profile of Each Cell Population.
Genomic profile of each cell population using oligonucleotide CGH arrays. Reported as unique probes on the CGH array.
Time frame: Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months
Population: One of the cases that had FFPE blocks for the study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Vorinostat) | Unique Probes on the Oligonucleotide CGH Array as a Measure of the Genomic Profile of Each Cell Population. | 442,892 unique probes on the CGH arrays |